Cytokinetics, Inc.

Cytokinetics, Inc. has recently revised its evaluation amid changing market conditions. The company's stock is priced at $60.03, with a notable 15.84% return over the past year. Over five years, it has achieved a remarkable 259.03% return, showcasing its resilience in the competitive pharmaceuticals sector.

Cytokinetics, Inc. has achieved a new 52-week high of USD 64.13, significantly up from its low of USD 29.31. The company, with a market cap of USD 6,233 million, shows a 14.94% performance increase over the past year and maintains a low debt-to-equity ratio and high return on equity.

Cytokinetics, Inc. has experienced notable stock fluctuations, with a current price of $58.44. The company has shown resilience, achieving a 22.88% return over the past month and a 24.23% year-to-date return, significantly outperforming the S&P 500. Its five-year return stands at 254.83%.

Cytokinetics, Inc. achieved a new 52-week high of USD 63.86 on October 15, 2025, reflecting a strong performance over the past year. With a market capitalization of USD 6,233 million, the company demonstrates solid financial health, including a low debt-to-equity ratio and a high return on equity.

Cytokinetics, Inc. has achieved a new 52-week high, reflecting strong performance over the past year. The company, with a market capitalization of USD 6,233 million, shows impressive financial metrics, including a high return on equity. It maintains a low debt-to-equity ratio and does not offer dividends.

Cytokinetics, Inc. has achieved a new 52-week high of USD 61.42, reflecting strong performance over the past year. With a market capitalization of USD 6,233 million, the company shows a manageable debt-to-equity ratio of 0.31 and an impressive return on equity of 157.39%, despite operating at a loss.

Cytokinetics, Inc. has achieved a new 52-week high, reflecting a strong upward trend in its stock performance over the past year. With a market capitalization of USD 6,233 million, the company shows a manageable debt-to-equity ratio and a high return on equity, despite not offering dividends.

Cytokinetics, Inc. has achieved a new 52-week high, reflecting a significant year-over-year performance. With a market capitalization of USD 6,233 million, the company demonstrates strong efficiency in generating returns on equity despite being loss-making. Its low debt-to-equity ratio indicates a conservative approach to leverage.

Cytokinetics, Inc. has experienced notable stock performance recently, with significant gains over the past week and month, contrasting with the S&P 500. Despite these short-term successes, the company has struggled over the past year and faces financial challenges, including a negative book value and weak debt servicing ability.

Cytokinetics, Inc. has recently revised its evaluation amid changing market dynamics. The company's stock price has risen significantly, reflecting notable volatility over the past year. Technical indicators present a mixed outlook, while Cytokinetics has outperformed the S&P 500 in the short term, despite a decline over the past year.

Cytokinetics, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. Current technical indicators present a mixed outlook, with contrasting signals from daily and monthly trends. Despite a challenging year, the stock has shown recent improvement, outperforming the S&P 500 over the past month.

Cytokinetics, Inc. has recently revised its evaluation amid changing market conditions. The stock has experienced fluctuations, with mixed technical indicators reflecting varying trends. Performance-wise, it has underperformed annually compared to the S&P 500 but has shown significant growth over the past five years, surpassing the index.